Area of research
Oncology · Reproductive Medicine
Research interest
Research interests include PARP inhibition in cancer therapy, Ovarian cancer diagnosis and treatment, Cancer Genomics and Diagnostics, and BRCA gene mutations in cancer.
HRDetect in Ovarian Carcinoma: Stratification and Therapeutic Implications
BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance
TP53 somatic evolution in cervical liquid-based cytology and blood from individuals with and without ovarian cancer and BRCA1 or BRCA2 germline mutations
Diagnosis of Ovarian Carcinoma Homologous Recombination DNA Repair Deficiency From Targeted Gene Capture Oncology Assays
Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984
Homologous recombination–deficient mutation cluster in tumor suppressor <i>RAD51C</i> identified by comprehensive analysis of cancer variants
Acquired <i>RAD51C</i> Promoter Methylation Loss Causes PARP Inhibitor Resistance in High-Grade Serous Ovarian Carcinoma
Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513
Germline mutations in Black patients with ovarian, fallopian tube and primary peritoneal carcinomas
Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study
<i>BRCA</i> Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma